{"id":6649,"date":"2024-11-21T13:59:16","date_gmt":"2024-11-21T12:59:16","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=6649"},"modified":"2025-04-28T21:40:47","modified_gmt":"2025-04-28T19:40:47","slug":"pamiparib-in-combination-with-tislelizumab-in-patients-with-advanced-solid-tumours-results-from-the-dose-expansion-stage-of-a-multicentre-open-label-phase-i-trial","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/pamiparib-in-combination-with-tislelizumab-in-patients-with-advanced-solid-tumours-results-from-the-dose-expansion-stage-of-a-multicentre-open-label-phase-i-trial\/","title":{"rendered":"Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial\u00a0"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-6649","publication","type-publication","status-publish","hentry","disease_state-gastic-gastroesophageal-junction-cancer","disease_state-ovarian-cancer","disease_state-small-cell-lung-cancer","disease_state-triple-negative-breast-cancer","molecule-tislelizumab"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/6649","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=6649"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=6649"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}